Présentation de l'entreprise
CNS Pharmaceuticals, Inc. operates as a clinical pharmaceutical entity focused on the development of anti-cancer drug candidates specifically designed for the treatment of brain and central nervous system tumors. The company functions within the healthcare sector and the biotechnology industry, positioning itself as a specialized player in oncology research and therapeutic innovation. As of the latest data, the enterprise carries a market capitalization of $1.77 million, while annual revenue and employee count figures are not disclosed in the provided financial records. The minimal market capitalization relative to the high-risk nature of biotechnology development indicates that the company is in an early-stage growth phase, relying heavily on future clinical trial outcomes rather than established commercial sales to generate value.
Santé financière
The company reports a net income of -$15,850,564 and an EBITDA of -$15,982,641, while annual revenue data is unavailable, resulting in a zero gross margin, operating margin, and profit margin. The significant gap between reported revenue (which is not listed) and the substantial net loss highlights an aggressive cost structure typical of pre-commercial biotech firms where research and development expenses far exceed current income streams. Free cash flow stands at -$6,958,225, signaling that the company is burning cash to fund its operations and clinical trials, which limits immediate financial flexibility without external capital injections. The balance sheet shows cash reserves of $7.20 million against total debt of $328,571, creating a net cash position that suggests a conservative leverage strategy despite the high debt-to-equity ratio of 7.26. A current ratio of 1.98 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer for ongoing operational expenses. Return on equity is recorded at -296.3% and return on assets at -115.3%, metrics that reveal management is currently prioritizing capital deployment for long-term asset growth rather than generating immediate shareholder returns, a common characteristic of companies in the discovery phase of drug development.
Évaluation de la valorisation
The forward P/E ratio is listed as -5.59, while the trailing P/E ratio is not applicable due to the lack of positive earnings, a discrepancy that implies investors are valuing the company based on potential future profitability rather than current income generation. The price-to-book ratio stands at 0.13, indicating that the market is currently pricing the company's equity at a fraction of its book value, reflecting high risk premiums associated with clinical trial failures and the uncertainty of regulatory approval. Since revenue data is unavailable, the price-to-sales ratio is not applicable, and the EV/EBITDA multiple is 0.32, suggesting a very low enterprise valuation relative to earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week low of $2.06 and a 52-week high of $34.80, placing the current valuation context within a range of extreme volatility typical for small-cap biotechnology stocks. With a beta of 0.49, the stock exhibits lower price volatility relative to the broader market, suggesting that its price movements are less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both unavailable in the current financial dataset, preventing a direct comparison of growth rates between top-line sales and bottom-line profitability. As the company does not pay a dividend, with a dividend yield and payout ratio both listed as not applicable or zero, it retains all available earnings to reinvest into research and development activities rather than distributing income to shareholders. This reinvestment strategy is standard for clinical pharmaceutical companies that must fund expensive Phase 2 clinical trials for candidates like TPI 287 and Berubicin before achieving commercial viability. The overall growth and income profile is characterized by a complete absence of current income generation and growth metrics, relying entirely on the successful progression of its drug candidates through clinical stages to unlock future value.